
## Ajit P Limaye

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4957588/publications.pdf Version: 2024-02-01



AIT DI MAVE

#	Article	IF	CITATIONS
1	Polyomavirus-Associated Nephropathy in Renal Transplantation: Interdisciplinary Analyses and Recommendations. Transplantation, 2005, 79, 1277-1286.	1.0	842
2	Emergence of ganciclovir-resistant cytomegalovirus disease among recipients of solid-organ transplants. Lancet, The, 2000, 356, 645-649.	13.7	505
3	Cytomegalovirus Reactivation in Critically Ill Immunocompetent Patients. JAMA - Journal of the American Medical Association, 2008, 300, 413.	7.4	401
4	Coronavirus Disease 2019 in Solid Organ Transplant: A Multicenter Cohort Study. Clinical Infectious Diseases, 2021, 73, e4090-e4099.	5.8	332
5	Impact of Cytomegalovirus in Organ Transplant Recipients in the Era of Antiviral Prophylaxis. Transplantation, 2006, 81, 1645-1652.	1.0	217
6	High Incidence of Ganciclovirâ€Resistant Cytomegalovirus Infection among Lung Transplant Recipients Receiving Preemptive Therapy. Journal of Infectious Diseases, 2002, 185, 20-27.	4.0	216
7	Extended Valganciclovir Prophylaxis to Prevent Cytomegalovirus After Lung Transplantation. Annals of Internal Medicine, 2010, 152, 761.	3.9	212
8	Ganciclovirâ€Resistant Cytomegalovirus in Organ Transplant Recipients. Clinical Infectious Diseases, 2002, 35, 866-872.	5.8	175
9	Extended Valganciclovir Prophylaxis in D+/Râ^' Kidney Transplant Recipients is Associated With Long-Term Reduction in Cytomegalovirus Disease: Two-Year Results of the IMPACT Study. Transplantation, 2010, 90, 1427-1431.	1.0	175
10	Treatment of Refractory BK Virus-Associated Nephropathy With Cidofovir. American Journal of Transplantation, 2003, 3, 186-191.	4.7	166
11	Late-Onset Cytomegalovirus Disease in Liver Transplant Recipients Despite Antiviral Prophylaxis1. Transplantation, 2004, 78, 1390-1396.	1.0	141
12	Transmission ofHistoplasma capsulatumby Organ Transplantation. New England Journal of Medicine, 2000, 343, 1163-1166.	27.0	139
13	Marked Variability of BK Virus Load Measurement Using Quantitative Real-Time PCR among Commonly Used Assays. Journal of Clinical Microbiology, 2008, 46, 2671-2680.	3.9	138
14	Polyomavirus Nephropathy in Pediatric Kidney Transplant Recipients. American Journal of Transplantation, 2004, 4, 2109-2117.	4.7	136
15	Polyomavirus Nephropathy in Native Kidneys of Nonâ€Renal Transplant Recipients. American Journal of Transplantation, 2005, 5, 614-620.	4.7	112
16	Detection of Epstein-Barr Virus DNA in Sera from Transplant Recipients with Lymphoproliferative Disorders. Journal of Clinical Microbiology, 1999, 37, 1113-1116.	3.9	109
17	Pseudomembranous Colitis Caused by a Toxin A <sup>â^'</sup> B <sup>+</sup> Strain of <i>Clostridium difficile</i> . Journal of Clinical Microbiology, 2000, 38, 1696-1697.	3.9	104
18	Effect of Preemptive Therapy vs Antiviral Prophylaxis on Cytomegalovirus Disease in Seronegative Liver Transplant Recipients With Seropositive Donors. JAMA - Journal of the American Medical Association, 2020, 323, 1378.	7.4	103

#	Article	IF	CITATIONS
19	Treatment of Tularemia with Fluoroquinolones: Two Cases and Review. Clinical Infectious Diseases, 1999, 29, 922-924.	5.8	98
20	Incidence and Clinical Features of Ganciclovir- Resistant Cytomegalovirus Disease in Heart Transplant Recipients. Clinical Infectious Diseases, 2007, 45, 439-447.	5.8	96
21	Symptomatic Respiratory Virus Infection and Chronic Lung Allograft Dysfunction. Clinical Infectious Diseases, 2016, 62, 313-319.	5.8	92
22	Effect of Ganciclovir on IL-6 Levels Among Cytomegalovirus-Seropositive Adults With Critical Illness. JAMA - Journal of the American Medical Association, 2017, 318, 731.	7.4	91
23	Six Rapid Tests for Direct Detection of Clostridium difficile and Its Toxins in Fecal Samples Compared with the Fibroblast Cytotoxicity Assay. Journal of Clinical Microbiology, 2003, 41, 667-670.	3.9	84
24	A prospective multicenter observational study of cell-mediated immunity as a predictor for cytomegalovirus infection in kidney transplant recipients. American Journal of Transplantation, 2019, 19, 2505-2516.	4.7	84
25	Update and Review: State-of-the-Art Management of Cytomegalovirus Infection and Disease Following Thoracic Organ Transplantation. Transplantation Proceedings, 2011, 43, S1-S17.	0.6	83
26	Earliest cases of coronavirus disease 2019 (COVIDâ€19) identified in solid organ transplant recipients in the United States. American Journal of Transplantation, 2020, 20, 1885-1890.	4.7	82
27	Risk Factors and Outcomes of Ganciclovir-Resistant Cytomegalovirus Infection in Solid Organ Transplant Recipients. Clinical Infectious Diseases, 2017, 65, 57-63.	5.8	81
28	Cross-Reactivity of T Lymphocytes Recognizing a Human Cytotoxic T-Lymphocyte Epitope within BK and JC Virus VP1 Polypeptides. Journal of Virology, 2005, 79, 11170-11178.	3.4	80
29	CMV in critically ill patients: pathogen or bystander?. Reviews in Medical Virology, 2010, 20, 372-379.	8.3	74
30	Use of SARS-CoV-2-infected deceased organ donors: Should we always "just say no?― American Journal of Transplantation, 2020, 20, 1787-1794.	4.7	74
31	Varicella zoster virus in solid organ transplantation: Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice. Clinical Transplantation, 2019, 33, e13622.	1.6	71
32	Programmed Death–1 Expression in Liver Transplant Recipients as a Prognostic Indicator of Cytomegalovirus Disease. Journal of Infectious Diseases, 2008, 197, 25-33.	4.0	63
33	COVID-19—Lessons Learned and Questions Remaining. Clinical Infectious Diseases, 2021, 72, 2225-2240.	5.8	54
34	Statin Use and Bone Mineral Density in Renal Transplant Recipients. American Journal of Transplantation, 2003, 3, 1320-1321.	4.7	53
35	A Phase 2, Randomized, Double-blind, Placebo-Controlled Trial of Presatovir for the Treatment of Respiratory Syncytial Virus Upper Respiratory Tract Infection in Hematopoietic-Cell Transplant Recipients. Clinical Infectious Diseases, 2020, 71, 2777-2786.	5.8	53
36	Progress and Challenges in the Prevention, Diagnosis, and Management of Cytomegalovirus Infection in Transplantation. Clinical Microbiology Reviews, 2020, 34, .	13.6	45

#	Article	IF	CITATIONS
37	Antiviral resistance in cytomegalovirus: An emerging problem in organ transplant recipients. Seminars in Respiratory Infections, 2002, 17, 265-273.	1.3	44
38	Coreactivation of Human Herpesvirus 6 and Cytomegalovirus Is Associated With Worse Clinical Outcome in Critically III Adults*. Critical Care Medicine, 2015, 43, 1415-1422.	0.9	39
39	Presentation of BK polyomavirus–associated hemorrhagic cystitis after allogeneic hematopoietic cell transplantation. Blood Advances, 2020, 4, 617-628.	5.2	39
40	Outbreak ofStenotrophomonas maltophiliaBacteremia Among Patients Undergoing Bone Marrow Transplantation: Association With Faulty Replacement of Handwashing Soap. Infection Control and Hospital Epidemiology, 1999, 20, 756-758.	1.8	37
41	BK virus-associated nephropathy in kidney transplant recipients. Reviews in Medical Virology, 2004, 14, 193-205.	8.3	34
42	Letermovir treatment of cytomegalovirus infection or disease in solid organ and hematopoietic cell transplant recipients. Transplant Infectious Disease, 2021, 23, e13687.	1.7	34
43	Clinical Impact Associated with Corrected Results in Clinical Microbiology Testing. Journal of Clinical Microbiology, 2005, 43, 2188-2193.	3.9	30
44	SARS-CoV-2 Vaccines in Kidney Transplant Recipients: Will They Be Safe and Effective and How Will We Know?. Journal of the American Society of Nephrology: JASN, 2021, 32, 1021-1024.	6.1	28
45	Invasive Pneumococcal Infections in Adult Lung Transplant Recipients. American Journal of Transplantation, 2004, 4, 1366-1371.	4.7	27
46	Prospective Assessment of Cytomegalovirus Immunity in High-Risk Donor-Seropositive/Recipient-Seronegative Liver Transplant Recipients Receiving Either Preemptive Therapy or Antiviral Prophylaxis. Journal of Infectious Diseases, 2019, 220, 752-760.	4.0	27
47	Changing the paradigm of organ utilization from <scp>PHS</scp> increasedâ€risk donors: an opportunity whose time has come?. Clinical Transplantation, 2015, 29, 724-727.	1.6	24
48	Circulating exosomes with lung self-antigens as a biomarker for chronic lung allograft dysfunction: A retrospective analysis. Journal of Heart and Lung Transplantation, 2020, 39, 1210-1219.	0.6	24
49	Detection of SARS-CoV-2 by bronchoscopy after negative nasopharyngeal testing: Stay vigilant for COVID-19. Respiratory Medicine Case Reports, 2020, 30, 101120.	0.4	24
50	Primary response against cytomegalovirus during antiviral prophylaxis with valganciclovir, in solid organ transplant recipients. Transplant International, 2011, 24, 920-931.	1.6	22
51	Predictive Value of Respiratory Viral Detection in the Upper Respiratory Tract for Infection of the Lower Respiratory Tract With Hematopoietic Stem Cell Transplantation. Journal of Infectious Diseases, 2019, 221, 379-388.	4.0	22
52	Reported β-Lactam and Other Antibiotic Allergies in Solid Organ and Hematopoietic Cell Transplant Recipients. Clinical Infectious Diseases, 2020, 71, 1587-1594.	5.8	22
53	Infection control strategies that successfully controlled an outbreak of Mycobacterium abscessus at a cystic fibrosis center. American Journal of Infection Control, 2016, 44, 154-159.	2.3	21
54	Current Understanding of Cytomegalovirus Reactivation in Critical Illness. Journal of Infectious Diseases, 2020, 221, S94-S102.	4.0	21

#	Article	IF	CITATIONS
55	Emerging evidence to support not always "just saying no―to SARS-CoV-2 positive donors. American Journal of Transplantation, 2020, 20, 3261-3262.	4.7	20
56	Rapid Detection of Human Cytomegalovirus UL97 and UL54 Mutations Directly from Patient Samples. Journal of Clinical Microbiology, 2013, 51, 2354-2359.	3.9	18
57	Infections in Solid-Organ Transplant Recipients. , 2015, , 3440-3452.		18
58	Donorâ€derived hepatitis C in the era of increasing intravenous drug use: A report of the Disease Transmission Advisory Committee. Clinical Transplantation, 2018, 32, e13370.	1.6	16
59	Cost-effectiveness of Preemptive Therapy Versus Prophylaxis in a Randomized Clinical Trial for the Prevention of Cytomegalovirus Disease in Seronegative Liver Transplant Recipients With Seropositive Donors. Clinical Infectious Diseases, 2021, 73, e2739-e2745.	5.8	15
60	Expedited SARS-CoV-2 screening of donors and recipients supports continued solid organ transplantation. American Journal of Transplantation, 2020, 20, 3106-3112.	4.7	13
61	Quantitation of Cytomegalovirus DNA Load in Dried Blood Spots Correlates Well with Plasma Viral Load. Journal of Clinical Microbiology, 2013, 51, 2360-2364.	3.9	12
62	Respiratory virus infections and chronic lung allograft dysfunction: Assessment of virology determinants. Journal of Heart and Lung Transplantation, 2016, 35, 946-947.	0.6	12
63	Expanding access to transplantation with hepatitis Câ€positive donors: A new perspective on an old issue. Clinical Transplantation, 2017, 31, e12884.	1.6	11
64	Clinical characteristics and outcomes of lateâ€onset BK virus nephropathy in kidney and kidneyâ€pancreas transplant recipients. Transplant Infectious Disease, 2018, 20, e12928.	1.7	11
65	Risk Factors for Cytomegalovirus Reactivation and Association With Outcomes in Critically III Adults With Sepsis: A Pooled Analysis of Prospective Studies. Journal of Infectious Diseases, 2021, 223, 2108-2112.	4.0	11
66	Plasma IL-10 Levels to Guide Antiviral Prophylaxis Prevention of Late-Onset Cytomegalovirus Disease, in High Risk Solid Kidney and Liver Transplant Recipients. Transplantation, 2016, 100, 210-216.	1.0	10
67	Cytomegalovirus immunoglobulin G titers do not predict reactivation risk in immunocompetent hosts. Journal of Medical Virology, 2019, 91, 836-844.	5.0	10
68	Listing practices and graft utilization of hepatitis C–positive deceased donors in liver and kidney transplant. Surgery, 2019, 166, 102-108.	1.9	9
69	Transplant tourism complicated by lifeâ€threatening New Delhi metalloâ€Î²â€lactamaseâ€1 infection. American Journal of Transplantation, 2019, 19, 1224-1228.	4.7	9
70	Impact of valganciclovir prophylaxis duration on cytomegalovirus disease in highâ€risk donor seropositive/recipient seronegative heart transplant recipients. Transplant Infectious Disease, 2020, 22, e13255.	1.7	9
71	Comparison of Preemptive Therapy and Antiviral Prophylaxis for Prevention of Cytomegalovirus in Seropositive Liver Transplant Recipients. Transplantation, 2018, 102, 632-639.	1.0	8
72	Association of Donor and Recipient Cytomegalovirus Serostatus on Graft and Patient Survival in Liver Transplant Recipients. Liver Transplantation, 2021, 27, 1302-1311.	2.4	8

#	Article	IF	CITATIONS
73	ls Kidney Donor Profile Index (KDPI) Valid for Hepatitis C Aviremic Kidneys?. Annals of Transplantation, 2017, 22, 663-664.	0.9	8
74	Willingness to Consider Increased-Risk Donors: A Single-Center Experience in Kidney Transplantation. Annals of Transplantation, 2018, 23, 387-392.	0.9	8
75	A patient self-collection method for longitudinal monitoring of respiratory virus infection in solid organ transplant recipients. Journal of Clinical Virology, 2015, 62, 98-102.	3.1	7
76	Prediction of Infection After Solid Organ Transplantation: Is Measuring Cell-Mediated Immunity the Answer?. Clinical Infectious Diseases, 2018, 66, 1398-1399.	5.8	7
77	Xanthogranulomatous Pyelonephritis With Direct Extension Into the Liver. American Journal of Medicine, 2020, 133, 1054-1055.	1.5	6
78	Unexpected Cytomegalovirus (CMV) Replication Kinetics in CMV Donor-Seropositive, Recipient-Seronegative Liver Transplant Recipients Receiving Preemptive Antiviral Therapy. Journal of Infectious Diseases, 2022, 225, 436-442.	4.0	6
79	Tacrolimus: Unlikely Harmful and Perhaps Helpful in Liver Transplant Recipients with COVID-19. Gastroenterology, 2021, 160, 1012-1013.	1.3	6
80	Delayed Mortality Among Solid Organ Transplant Recipients Hospitalized for COVID-19. Clinical Infectious Diseases, 2024, 78, 711-718.	5.8	6
81	LB21. Preemptive Therapy (PET) vs. Prophylaxis for Prevention of Cytomegalovirus (CMV) Disease in High-Risk Donor Seropositive/Recipient Seronegative (D+Râ^') Liver Transplant Recipients (LTR): A NIH-Sponsored, Randomized, Controlled, Multicenter Trial. Open Forum Infectious Diseases, 2018, 5, S766-S766.	0.9	5
82	Trillions and Trillions: Herpes Simplex Virus–1 Hepatitis in an Immunocompetent Adult. Open Forum Infectious Diseases, 2019, 6, ofz465.	0.9	4
83	Variability in assessing for BK viremia: whole blood is not reliable and plasma is not above reproach - a retrospective analysis. Transplant International, 2017, 30, 670-678.	1.6	3
84	Risk Factors for Cytomegalovirus Viremia following Liver Transplantation With a Seropositive Donor and Seronegative Recipient Receiving Antiviral Therapy. Journal of Infectious Diseases, 2021, 223, 1073-1077.	4.0	3
85	Disseminated Mycobacterium haemophilum With Tenosynovitis in a Liver Transplant Recipient. Journal of Clinical Rheumatology, 2021, 27, e36-e37.	0.9	3
86	Systematic Assessment of Culture Review as a Tool to Assess Errors in the Clinical Microbiology Laboratory. Archives of Pathology and Laboratory Medicine, 2008, 132, 1792-1795.	2.5	3
87	Reply to Munoz and Santin. Clinical Infectious Diseases, 2014, 58, 905-906.	5.8	2
88	Comparison of self-collected nasal swabs with oral washes for sequential viral load monitoring in lung transplant recipients with respiratory virus infection. Journal of Clinical Virology, 2017, 91, 49-51.	3.1	2
89	Immunosuppression in solid organ transplant recipients with Covidâ€19: More data, but still complicated. Transplant Infectious Disease, 2021, 23, e13650.	1.7	2

90 Cytomegalovirus Infection After Solid Organ Transplantation. , 2016, , 441-475.

2

#	Article	IF	CITATIONS
91	Direct Detection of Legionellae in Respiratory Tract Specimens by Using Fluorescence In Situ Hybridization. , 0, , 221-224.		2
92	Changing landscape of hepatitis C virus-positive donors. World Journal of Hepatology, 2017, 9, 905.	2.0	2
93	Reply to Hage and Schuurmans. Clinical Infectious Diseases, 2021, 73, e2833-e2834.	5.8	2
94	Apples to Apples: The Challenges of Studying COVIDâ€19 Mortality in Solid Organ Transplant Recipients. American Journal of Transplantation, 2022, , .	4.7	2
95	Misplaced emphasis, misunderstood risk: a cultural history of Public Health Service infectious disease guidelines. Current Opinion in Organ Transplantation, 2022, 27, 159-164.	1.6	2
96	Vaccination, Transplantation, and a Social Contract. Journal of the American Society of Nephrology: JASN, 2022, 33, 1445-1447.	6.1	2
97	Time to Antibiotics in Solid Organ Transplant Recipients With Gram-Negative Rod Bloodstream Infections. Clinical Infectious Diseases, 2015, 60, 1868-1869.	5.8	1
98	A Prospective Study Comparing Self-Collected Nasal Swabs to Oral Washes for Monitoring Viral Load Kinetics in Lung Transplant Recipients With Respiratory Virus Infection. Open Forum Infectious Diseases, 2016, 3, .	0.9	1
99	NAT testing in recipients of hepatitis C aviremic donor organs. American Journal of Transplantation, 2018, 18, 1030.	4.7	1
100	Hepatitis C NAT status in the UNOS database. American Journal of Transplantation, 2019, 19, 1870.	4.7	1
101	Examining valganciclovir prophylaxis duration among highâ€risk donor seropositive/recipient seronegative heart transplant recipients in a larger cohort. Transplant Infectious Disease, 2021, 23, e13581.	1.7	1
102	1225Co-Reactivation of Human Herpesvirus 6 (HHV-6) and Cytomegalovirus (CMV) is Associated with Worse Clinical Outcome in Critically III Immunocompetent Adults. Open Forum Infectious Diseases, 2014, 1, S43-S43.	0.9	0
103	Letter to the Editor. Clinical Infectious Diseases, 2020, 70, 719.	5.8	0
104	In with the new and, mostly better: Considering the OPTN bloodâ€borne virus policy updates. American Journal of Transplantation, 2021, 21, 3494-3495.	4.7	0
105	Functional Comparison and Longitudinal Assessment of Tri-Functional T-Cells Recognizing CMV pp65 and IE-1 Polypeptides in Hematopoietic Stem Cell and Solid Organ Transplant Recipients Blood, 2006, 108, 2936-2936.	1.4	0
106	Human Polyomaviruses. , 2008, , 1058-1062.		0
107	A Dark Horse Diagnosis. Journal of Hospital Medicine, 2018, 13, 790-794.	1.4	0
108	Multiple liver lesions in a lung transplant recipient. American Journal of Transplantation, 2021, 21, 3801-3803.	4.7	0

#	Article	IF	CITATIONS
109	Donor CMV Reactivation as a Novel Risk Factor for CMV Replication in Seropositive Liver Transplant Recipients. Transplantation Direct, 2021, 7, e637.	1.6	0